Sichenzia Ross Ference Kesner LLP Represents Tonix Pharmaceuticals in $5.2 Million Public Offering
Press Release – New York, NY – November 1, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Ference Kesner LLP announced today that it represented Tonix Pharmaceuticals Holding Corp. (NASDAQ “TNXP”), a developer of next-generation medicines for common disorders of the central nervous system, with its lead program focusing on post traumatic stress disorder, in an underwritten public offering of 9,500,000 units, with each unit consisting of one (1) share of common stock and a warrant to purchase one-half (0.5) of a share of common stock. The Units were sold at a public offering price of $0.55 per Unit, for aggregate gross proceeds of $5.2 million. Dawson James Securities, Inc. acted as the sole book-running manager for the offering.
The Sichenzia Ross Ference Kesner LLP team was led by partners Marc J. Ross and James M. Turner and associate S. Ashley Jaber.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Attorneys Mendy Piekarski and Jay Kaplowitz Achieve Successful Settlement of Cryptocurrency Lawsuit - May 21, 2018
- Sichenzia Ross Ference Kesner LLP Represents Pareteum Corporation in $6.1 Million Registered Direct Offering - May 14, 2018
- Partner Harvey Kesner Publishes Article on SEC and Cryptocurrency in Law360 - May 9, 2018